{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:19:44Z","timestamp":1783948784316,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Botulinum type-A toxin is a well established aesthetic and medical treatment. While the usage of type-B toxin is less common, there is a growing interest in using type-B toxin, especially in those who are treatment resistant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the primary FDA-approved clinical applications of rimabotulinumtoxinB, along with established and emerging off-label clinical indications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIAL AND METHODS<\/jats:title>\n            <jats:p>Articles were reviewed from PubMed database and Food and Drug Adminstration guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Facial rhytids tend to use a higher conversion ratio between type A and type B toxin, due to type B toxin's weaker affinity to muscles and higher affinity for sweat glands. Specially, a 1:100 to 1:50 ratio was utilized for glabellar rhytids, a 1:25 to 1:50 ratio for periocular rhytids, a 1:50 to 1:66.6 ratio for cervical dystonia, a 1:20 to 1:50 ratio for hyperhidrosis, and a 1:25 to 30 ratio for sialorrhea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Type B toxin has demonstrated its safety and efficacy in treating facial rhytids, cervical dystonia, sialorrhea and hyperhidrosis, with potential for novel applications under investigation. Regardless of injection location and clinical applications, dry mouth and dysphagia remained the most common side effects. Across all indications, type B toxin appeared to have a faster onset of action, a dose-dependent clinical duration, and a dose-dependent adverse effect profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004253","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:54:35Z","timestamp":1724889275000},"page":"S52-S57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["RimabotulinumtoxinB: An Update"],"prefix":"10.1097","volume":"50","author":[{"given":"Teresa","family":"Song","sequence":"first","affiliation":[{"name":"Marmur Medical, New York, New York;"},{"name":"Department of Dermatology, The Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen S.","family":"Marmur","sequence":"additional","affiliation":[{"name":"Marmur Medical, New York, New York;"},{"name":"Department of Dermatology, The Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"Suppl 5","key":"R1-20241006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","article-title":"Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions","volume":"8","author":"Aoki","year":"2001","journal-title":"Eur J Neurol"},{"key":"R3-20241006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/toxins12050332","article-title":"FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia","volume":"12","author":"Spiegel","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R4-20241006","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1128\/IAI.73.9.5450-5457.2005","article-title":"Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization","volume":"73","author":"Smith","year":"2005","journal-title":"Infect Immun"},{"key":"R6-20241006","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"R7-20241006","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-4632.2004.02531.x","article-title":"Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis","volume":"44","author":"Baumann","year":"2005","journal-title":"Int J Dermatol."},{"key":"R8-20241006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14764170260030126","article-title":"Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis","volume":"4","author":"Spencer","year":"2002","journal-title":"J Cosmet Laser Ther"},{"key":"R10-20241006","first-page":"496","article-title":"Botulinum toxin type B (Myobloc)","volume":"29","author":"Baumann","year":"2003","journal-title":"Dermatol Surg."},{"key":"R11-20241006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14764170260030117","article-title":"Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing","volume":"4","author":"Lowe","year":"2002","journal-title":"J Cosmet Laser Ther"},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R13-20241006","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1542\/peds.68.1.50","article-title":"Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations","volume":"68","author":"Santos","year":"1981","journal-title":"Pediatrics"},{"key":"R15-20241006","first-page":"817","article-title":"Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study","volume":"28","author":"Sadick","year":"2002","journal-title":"Dermatol Surg"},{"key":"R16-20241006","first-page":"501","article-title":"Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles","volume":"29","author":"Sadick","year":"2003","journal-title":"Dermatol Surg"},{"key":"R17-20241006","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1111\/j.1524-4725.2006.32333.x","article-title":"Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines","volume":"33","author":"Carruthers","year":"2007","journal-title":"Dermatol Surg"},{"key":"R18-20241006","first-page":"7","article-title":"Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides","volume":"29","author":"Matarasso","year":"2003","journal-title":"Dermatol Surg"},{"key":"R19-20241006","first-page":"508","article-title":"A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial","volume":"29","author":"Baumann","year":"2003","journal-title":"Dermatol Surg"},{"key":"R20-20241006","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/toxins12110677","article-title":"Transient improvement after switch to low doses of RimabotulinumtoxinB in patients resistant to AbobotulinumtoxinA","volume":"12","author":"Hefter","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R21-20241006","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"R22-20241006","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov Disord"},{"key":"R23-20241006","first-page":"CD004315","article-title":"Botulinum toxin type B for cervical dystonia","volume":"2016","author":"Marques","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"R24-20241006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","article-title":"Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia","volume":"20","author":"Berman","year":"2005","journal-title":"Mov Disord"},{"key":"R25-20241006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNF.0b013e318263163c","article-title":"Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials","volume":"35","author":"Chinnapongse","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"R26-20241006","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"R27-20241006","doi-asserted-by":"crossref","first-page":"100374","DOI":"10.1016\/j.ensci.2021.100374","article-title":"Efficacy of botulinum toxin type B (rimabotulinumtoxinB) in patients with cervical dystonia previously treated with botulinum toxin type A: a post-marketing observational study in Japan","volume":"25","author":"Kaji","year":"2021","journal-title":"eNeurologicalSci"},{"key":"R28-20241006","first-page":"CD004314","article-title":"Botulinum toxin type A versus botulinum toxin type B for cervical dystonia","volume":"10","author":"Duarte","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"R29-20241006","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/01.wnl.0000174433.76707.8c","article-title":"Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial","volume":"65","author":"Tintner","year":"2005","journal-title":"Neurology"},{"key":"R30-20241006","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and efficacy of RimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial","volume":"77","author":"Isaacson","year":"2020","journal-title":"JAMA Neurol"},{"key":"R31-20241006","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov Disord"},{"key":"R32-20241006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40734-017-0055-1","article-title":"RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials","volume":"4","author":"Dashtipour","year":"2017","journal-title":"J Clin Mov Disord"},{"key":"R33-20241006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00403-003-0440-5","article-title":"Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study","volume":"295","author":"Hecht","year":"2004","journal-title":"Arch Dermatol Res."},{"key":"R34-20241006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2003.11.001","article-title":"Botulinum toxin-B and the management of hyperhidrosis","volume":"22","author":"Baumann","year":"2004","journal-title":"Clin Dermatol"},{"key":"R35-20241006","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00415-002-0929-4","article-title":"Botulinum toxin type B for treatment of axillar hyperhidrosis","volume":"249","author":"Dressler","year":"2002","journal-title":"J Neurol"},{"key":"R36-20241006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bjps.2004.07.003","article-title":"Botulinum toxin type B: a new therapy for axillary hyperhidrosis","volume":"58","author":"Nelson","year":"2005","journal-title":"Br J Plast Surg."},{"key":"R37-20241006","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archdermatol.2010.408","article-title":"Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months","volume":"147","author":"Frasson","year":"2011","journal-title":"Arch Dermatol"},{"key":"R38-20241006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00042728-200503000-00002","article-title":"Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis","volume":"31","author":"Baumann","year":"2005","journal-title":"Dermatol Surg"},{"key":"R39-20241006","first-page":"497","article-title":"Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study","volume":"306","author":"Basciani","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"R40-20241006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/SAP.0000000000002666","article-title":"The use of botulinum toxin to prevent anastomotic thrombosis and promote flap survival: a bridge to developing clinical studies","volume":"87","author":"Hassan","year":"2021","journal-title":"Ann Plast Surg"},{"key":"R41-20241006","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"R42-20241006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/toxins15020147","article-title":"Efficacy and safety of botulinum toxin B in focal hyperhidrosis: a narrative review","volume":"15","author":"Campanati","year":"2023","journal-title":"Toxins (Basel)."},{"key":"R43-20241006","doi-asserted-by":"crossref","first-page":"e4407","DOI":"10.1097\/GOX.0000000000004407","article-title":"Emerging trends in botulinum neurotoxin A resistance: an international multidisciplinary review and consensus","volume":"10","author":"Ho","year":"2022","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R44-20241006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0733-8635(03)00040-8","article-title":"Comparison of botulinum toxins A and B in the treatment of facial rhytides","volume":"22","author":"Sadick","year":"2004","journal-title":"Dermatol Clin"},{"key":"R45-20241006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"R46-20241006","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.febslet.2011.12.037","article-title":"Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity","volume":"586","author":"Strotmeier","year":"2012","journal-title":"FEBS Lett"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T03:15:51Z","timestamp":1728184551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":42,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004253","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}